Efferent Labs at Bio International 2018
FOR IMMEDIATE RELEASE Efferent Labs™ at 2018 BIO International Convention (BUFFALO, NY) April 15, 2018 – Efferent Labs CEO Bill…
Read moreEfferent Labs at NYBio 2018
FOR IMMEDIATE RELEASE Efferent Labs™ at 2018 NewYorkBIO (BUFFALO, NY) April 24, 2016 – Efferent Labs will present the CytoComm™…
Read moreEfferent Labs Taps Evotec to Advance Implantable Biosensor for R&D, Oncology
FierceBiotech Efferent Labs has inked a deal with Evotec to develop its implantable biosensor technology. The device, which is injected…
Read moreLife-Sciences Accelerator Program Selects Efferent Labs
The Buffalo News Efferent Labs chosen to participate in Life-science accelerator program. Click here to read the entire article
Read moreCould a Biosensor Help Personalize Cancer Treatment?
WGRZ Innovate WNY – Could a Biosensor Help Personalize Cancer Treatment? Click here to watch the video.
Read moreRaland Therapeutics is Now Efferent Labs
Rochester Democrat & Chronicle Raland Therapeutics Inc., a developer of medical technology devices, has changed its name to Efferent Labs, Inc. Click…
Read moreImplantable Sensor Would Detect Changes in Body Before Health Problems Arise
News 8 WROC Rochester Efferent Labs CMO Dr. Spencer Rosero discusses Efferent’s disruptive technology. Click here to watch the video
Read moreMaking the Promise of Personalized Medicine a Reality
Businessinterviews.com Efferent Labs CEO Bill Rader speaks with Businessinterviews.com to discuss CytoComm™ and the life sciences landscape. Click here to read…
Read moreTech bubble? Pro: Focus on disruptive companies
CNBC Efferent Chairman Carl Yankowski discusses our disruptive technology, CytoComm™, on Fast Money Half Time Report. Click here to watch…
Read more